Giuseppe Mancia Selected Research

Gliclazide (Diamicron)

1/2022	Effects of glucose and blood pressure reduction on subclinical cardiac damage: Results from ADVANCE.
1/2021	The Impact of Frailty on the Effectiveness and Safety of Intensive Glucose Control and Blood Pressure-Lowering Therapy for People With Type 2 Diabetes: Results From the ADVANCE Trial.
1/2021	History of lower-limb complications and risk of cancer death in people with type 2 diabetes.
1/2021	Sex differences in risk factors for cognitive decline and dementia, including death as a competing risk, in individuals with diabetes: Results from the ADVANCE trial.
12/2020	Alternative kidney filtration markers and the risk of major macrovascular and microvascular events, and all-cause mortality in individuals with type 2 diabetes in the ADVANCE trial.
1/2020	Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A1c in the ADVANCE Trial.
11/2019	The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study.
1/2019	Effects of Blood Pressure Lowering on Clinical Outcomes According to Baseline Blood Pressure and Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus.
1/2019	Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus.
1/2018	Associations between body mass index and the risk of renal events in patients with type 2 diabetes.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Giuseppe Mancia Research Topics

Disease

162	Hypertension (High Blood Pressure) 01/2022 - 03/2002
53	Type 2 Diabetes Mellitus (MODY) 01/2022 - 01/2006
44	Cardiovascular Diseases (Cardiovascular Disease) 04/2022 - 09/2002
38	Heart Failure 01/2022 - 04/2002
35	Vascular Diseases (Vascular Disease) 01/2022 - 04/2009
31	Stroke (Strokes) 04/2022 - 06/2002
23	Obesity 01/2022 - 09/2003
22	Metabolic Syndrome (Dysmetabolic Syndrome X) 10/2020 - 09/2006
17	Atherosclerosis 01/2020 - 08/2002
16	Myocardial Infarction 04/2022 - 11/2004
15	Diabetes Mellitus 01/2021 - 08/2005
13	Coronary Artery Disease (Coronary Atherosclerosis) 06/2021 - 12/2003
13	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 01/2021 - 10/2004
11	Essential Hypertension 01/2020 - 08/2002
11	Insulin Resistance 01/2019 - 08/2002
10	Chronic Renal Insufficiency 01/2022 - 12/2010
9	Chronic Kidney Failure (Chronic Renal Failure) 01/2022 - 03/2009
8	COVID-19 01/2022 - 01/2020
8	Atrial Fibrillation 06/2021 - 03/2003
8	Carotid Artery Diseases 01/2019 - 11/2002
7	Renal Insufficiency (Renal Failure) 01/2021 - 12/2004
7	Isolated Systolic Hypertension 01/2018 - 01/2003
7	Hypoxia (Hypoxemia) 01/2017 - 09/2006
6	Hypertrophy 01/2021 - 01/2006
5	Erectile Dysfunction 01/2022 - 12/2004
5	Fibrosis (Cirrhosis) 11/2021 - 05/2005
5	Obstructive Sleep Apnea 01/2019 - 08/2002
5	Neoplasms (Cancer) 02/2016 - 04/2011
5	Abdominal Obesity 12/2011 - 12/2004
4	Infections 01/2022 - 03/2011
4	Hemorrhage 06/2021 - 06/2012
4	Iron Overload 11/2020 - 08/2002
4	Overweight 01/2019 - 12/2008
4	Cerebrovascular Disorders (Cerebrovascular Occlusion) 10/2018 - 05/2012
4	White Coat Hypertension 08/2015 - 08/2011
4	Albuminuria 10/2014 - 07/2011
4	Dyslipidemias (Dyslipidemia) 05/2013 - 09/2006
3	Left Ventricular Dysfunction 01/2022 - 01/2005
3	Body Weight (Weight, Body) 11/2021 - 08/2005
3	Diabetes Complications 10/2021 - 01/2018
3	Dementia (Dementias) 01/2021 - 10/2012
3	Heart Diseases (Heart Disease) 01/2021 - 10/2018
3	Weight Loss (Weight Reduction) 01/2021 - 08/2014
3	Gout 10/2020 - 09/2015
3	Kidney Diseases (Kidney Disease) 10/2020 - 05/2016

Drug/Important Bio-Agent (IBA)

94	Antihypertensive Agents (Antihypertensives)IBA 04/2022 - 03/2002
36	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 09/2003
35	Gliclazide (Diamicron)IBA 01/2022 - 06/2008
34	perindopril drug combination indapamideIBA 01/2022 - 04/2009
22	Adrenergic Agents (Adrenergic Drugs)IBA 01/2020 - 03/2003
21	Telmisartan (Micardis)FDA Link 01/2021 - 03/2008
20	Angiotensin Receptor AntagonistsIBA 01/2021 - 09/2003
19	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2022 - 04/2002
19	CholesterolIBA 01/2021 - 07/2002
19	Atenolol (Tenormin)FDA LinkGeneric 01/2020 - 11/2002
18	Pharmaceutical PreparationsIBA 01/2020 - 09/2002
17	DiureticsIBA 01/2022 - 03/2002
17	CreatinineIBA 01/2022 - 12/2004
16	Perindopril FDA LinkGeneric 01/2022 - 04/2009
15	Blood Glucose (Blood Sugar)IBA 01/2022 - 06/2005
15	Norepinephrine (Noradrenaline)FDA LinkGeneric 01/2021 - 09/2004
15	lacidipineIBA 01/2020 - 11/2002
13	Hydrochlorothiazide (Esidrix)FDA LinkGeneric 01/2022 - 09/2003
13	Indapamide FDA LinkGeneric 01/2022 - 04/2009
13	Ramipril (Altace)FDA LinkGeneric 01/2021 - 03/2008
12	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 01/2020 - 01/2006
10	SodiumIBA 01/2022 - 09/2006
10	Valsartan (Vals)FDA Link 01/2021 - 04/2002
10	Uric Acid (Urate)IBA 10/2020 - 12/2004
10	Nifedipine (Adalat)FDA LinkGeneric 01/2016 - 03/2002
8	Biomarkers (Surrogate Marker)IBA 01/2022 - 04/2012
8	Amlodipine (Norvasc)FDA LinkGeneric 01/2020 - 07/2006
8	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2018 - 02/2010
8	CalciumIBA 12/2016 - 11/2002
7	Hypoglycemic Agents (Hypoglycemics)IBA 01/2022 - 06/2005
7	AlbuminsIBA 01/2021 - 10/2014
7	LipidsIBA 01/2021 - 12/2004
7	trandolapril (Mavik)FDA LinkGeneric 01/2016 - 12/2003
7	Verapamil (Calan)FDA LinkGeneric 01/2016 - 10/2004
6	Triglycerides (Triacylglycerol)IBA 01/2019 - 05/2006
5	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 09/2020 - 02/2008
5	lercanidipineIBA 01/2019 - 01/2006
5	LDL CholesterolIBA 01/2019 - 04/2012
4	Drug CombinationsIBA 01/2021 - 03/2016
4	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 01/2020 - 12/2004
4	Insulin (Novolin)FDA Link 01/2020 - 09/2003
4	Retinaldehyde (Retinal)IBA 01/2018 - 06/2009
4	Oxygen (Dioxygen)IBA 01/2018 - 04/2013
4	IronIBA 03/2016 - 08/2002
4	candesartan cilexetil (Amias)FDA Link 01/2016 - 09/2003
4	Endothelins (Endothelin)IBA 04/2007 - 01/2005
3	Ferritins (Ferritin)IBA 11/2020 - 08/2002
3	Nebivolol FDA Link 01/2020 - 12/2003

Therapy/Procedure

58	Therapeutics 01/2022 - 05/2004
27	Denervation 01/2022 - 05/2012
7	Glycemic Control 01/2021 - 06/2008
5	Drug Therapy (Chemotherapy) 12/2019 - 05/2004
5	Catheters 01/2017 - 05/2012
3	Kidney Transplantation 01/2021 - 03/2013
3	Secondary Prevention 10/2020 - 06/2002